Share on StockTwits

Cocrystal Pharma (NASDAQ:COCP) Director Phillip Md Et Al Frost acquired 111,200 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $0.29 per share, for a total transaction of $32,248.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Cocrystal Pharma (NASDAQ:COCP) remained flat at $0.33 during during mid-day trading trading on Wednesday. The stock had a trading volume of 208,147 shares. Cocrystal Pharma has a 52 week low of $0.23 and a 52 week high of $0.97. The stock has a 50-day moving average of $0.29 and a 200-day moving average of $0.42. The company’s market cap is $40.1 million.

Cocrystal Pharma Inc, formerly Biozone Pharmaceuticals, Inc, through its wholly owned subsidiary, BioZone Laboratories, Inc (NASDAQ:COCP), primarily is engaged in the business of developing and manufacturing over the counter (OTC) drug products and cosmetic and beauty products on behalf of third parties.

Receive News & Ratings for Cocrystal Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.